Selective Progesterone Receptor Modulators (SPRMs)

Kristof Chwalisz, Chwalisz K, Kristof Chwalisż, Ramesh Garg, Garg R, Ramesh C. Garg, Brenner RM, Robert Brenner, Robert M Brenner, Schubert G, G. Schubert, Gerd Schubert, Elger W, Walter Elger, W Elger
Annals of the New York Academy of Sciences · 2002 · vol. 955(1) , pp. 373–388 · doi:10.1111/j.1749-6632.2002.tb02798.x · PMID:11949964 · W2095215260
review OA: closed CC0 ⤵ 48 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-10 ⓘ

This review discusses selective progesterone receptor modulators (SPRMs) as a potential therapeutic strategy for endometriosis, highlighting their potential advantages over current treatments due to endometrial selectivity and favorable pharmacology.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis, the presence of endometrial tissue outside the uterus, is a progressive, estrogen-dependent disease and occurs nearly exclusively in menstruating women of reproductive age. Pain syndrome, however, represents the major clinical problem of this disease, manifested as dysmenorrhea, pelvic pain, lower abdominal pain, and dyspareunia. The manifestation of the disease, that is, the pain syndrome, rather than the disease itself currently represents the major indication for both the medical and surgical therapies of endometriosis. The major drawbacks of current medical therapies of endometriosis are sometimes severe side effects. In this review, selective progesterone receptor modulators (SPRMs, mesoprogestins) as a potential therapeutic concept in endometriosis are discussed. Due to endometrial selectivity and favorable pharmacological profile, SPRMs may have advantages over the current medical treatments of this disease. Other emerging therapeutic approaches for this disease are also mentioned.

My notes (saved in your browser only)

Condition tags

endometriosisdysmenorrheadyspareunia

MeSH descriptors

Endometriosis Hormone Antagonists Receptors, Progesterone Animals Endometriosis Endometriosis Female Hormone Antagonists Hormone Antagonists Humans Ovulation Ovulation Pregnancy Prostaglandins Prostaglandins Receptors, Progesterone Receptors, Progesterone Uterus Uterus Uterus

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (30)

Cited by (49)

Source provenance

europepmc
last seen: 2026-08-27T06:11:05.884134+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:13:07.520820+00:00
unpaywall
last seen: 2026-08-27T06:26:25.619941+00:00
License: CC0 · commercial use OK